MindMed works to improve patient outcomes through a pipeline of novel drug candidates, focusing on the therapeutic potential of psychedelics and other compounds to address unmet needs in psychiatry, addiction, pain, and neurology.

MindMed

Our COVID-19 SafetyNet

NeuroPain

Sema4 Works

pooply

IPhone / Mobile Compatible

Viewport Meta

Domain Not Resolving

Euro

Google Tag Manager

HSTS

Google Analytics

WordPress

Global Site Tag

Organization Schema

Chief Medical Officer

Dan Karlin

Chief Commercial Officer

Francois Lilienthal

Chief Executive Officer

Robert Barrow

Vice President, Global Regulatory Affairs

Bridget Walton

VP, Programs and Portfolio Office

Carole Abel

VP Business Operations & Development

Nico Forte

Operations

Peter Mack

Vice President, Head of Development

Robert Silva

Sales and Support

Amber Doty

Amy Engel

Matthias Liechti

Matthew W. Johnson

Suzanne L. Bruhn

Peter Gasser

Stanley D. Glick

Bruce Linton

Natalie Wheeler

Kim Kuypers

Daniel Karlin

Miri Halperin Wernli

Executive President and Board Director

Bradford Cross

Chief Technology Officer

Schond L Greenway

Chief Financial Officer

Stephanie Fagan

Chief Corporate Affairs Officer

Madeline Feldman

Director of Strategy & Operations

New York Public Companies With More Than 50 Employees

Talent Resources Ventures Portfolio Companies

Health Care Public Companies With Fewer Than 1000 Employees

Pharmaceutical Public Companies With More Than 100 Employees

MindMed provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC.

Post-IPO Equity - MindMed

K2 HealthVentures

Post-IPO Debt - MindMed

Canaccord Genuity Group

Pre Seed Round - MindMed

Computer and Software Services and Scientific Services

New York

United States

North America

MindMed call volume above normal and directionally bullish

Psychedelic Drugs Market Size on Track to Surpass USD 8.85 Billion by 2032 at a 13.2% CAGR | VMR

AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?

Rising Incidence of Cancer: A Key Driver Transforming the Liposomal Drug Delivery Devices Market 2024

MindMed Announces New Employee Inducement Grants

Psychedelics Company MindMed Prices Public Offering Aiming To Raise $75M

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

MindMed appoints chief corporate affairs officer

A drug candidate with potential applications in psychiatry, pain, and substance use disorders.

A version of MDMA being explored for its effects on social functioning in ASD, with a safety and tolerability profile that may allow for standard dosing.

Involves patient education, engagement, and preparation, in-session monitoring, clinician decision support, and post-treatment health maintenance using AI models.

MindMed conducts clinical trials to evaluate the safety and efficacy of their investigational medications, with information available on clinicaltrials.gov.

A policy outlining the conditions under which patients might receive investigational medications outside of clinical trials, primarily through clinical trial participation.

Germany

Europe

Canada

Poland

Switzerland

HTML5

jQuery

Wordpress

GoDaddy Premium DNS

Microsoft Outlook

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Mind Medicine (MindMed) Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 16, 2024 6:08 AM	bd3c765b
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 16, 2024 6:08 AM	ecfe2cf7
crunchbase trigger	general	Nov 27, 2024 12:50 PM	e93afa5a
crunchbase profile	general	Nov 28, 2024 9:47 AM	41987b76
li profile	general
translate crunchbase fundingrounds	general	Nov 28, 2024 11:13 AM	94ae0e4b
peers	general	Oct 16, 2024 6:08 AM	677bb5b0
news basic	general	Oct 16, 2024 6:08 AM	13cba3dc
bundesanzeiger	filings
financials download nd	financials
private financials	financials

CO:MINDMED

MindMed

Last Close

7.09

22/11 21:00

Market Cap

500.56M

Beta: -

Volume Today

1.02M

Avg: -